WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The
Antimicrobials Working Group (AWG), a coalition of companies with
the mission to combat drug-resistant infections and spur
life-saving innovations, today announced that eleven of its member
companies will present data from their clinical and research
programs at IDWeek 2019 to be held October
2-6, 2019 in Washington
D.C.
IDWeek is the joint annual meeting of the Infectious Diseases
Society of America (IDSA), Society for Healthcare Epidemiology of
America (SHEA), the HIV Medical Association (HIVMA), and the
Pediatric Infectious Diseases Society (PIDS) that brings together
infectious disease professionals to present and discuss the latest
approaches in prevention, diagnosis, treatment, and epidemiology of
infectious diseases.
"AWG members look forward to joining their peers in the
scientific community, from around the world, to present and discuss
the newest innovations to combat drug-resistant infections," said
Evan Loh, M.D., Chief Executive
Officer of Paratek Pharmaceuticals and Chairman of the AWG. "AWG
companies will highlight progress in their clinical and research
programs in antifungal, antibacterial, and non-traditional
therapies in 52 presentations during the conference. These efforts
underscore the coalition's commitment to developing new
antimicrobial medicines for serious and life-threatening infectious
diseases."
The following AWG member companies will be presenting at IDWeek
2019: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Cidara
Therapeutics Inc., Entasis Therapeutics Inc., Melinta Therapeutics
Inc., Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc.,
Qpex Biopharma, Inc., SCYNEXIS Inc., Summit Therapeutics plc, and
VenatoRx Pharmaceuticals, Inc.
For more information on AWG member company presentations and
access to specific abstracts, please visit:
https://www.antimicrobialsworkinggroup.org/idweek-2019/
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective
power to improve the regulatory, investment, and commercial
environment for emerging infectious disease companies. Today, AWG
is comprised of thirteen antimicrobials companies: Amplyx
Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc.
(NASDAQ: CDTX), Entasis Therapeutics Inc. (NASDAQ: ETTX), Iterum
Therapeutics Ltd. (NASDAQ: ITRM), Melinta Therapeutics Inc.
(NASDAQ: MLNT), Nabriva Therapeutics US Inc. (NASDAQ: NBRV),
Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), Qpex Biopharma, Inc.,
SCYNEXIS Inc. (NASDAQ: SCYX), Summit Therapeutics plc (NASDAQ:
SMMT; AIM: SUMM), VenatoRx Pharmaceuticals, Inc., and X-Biotix
Therapeutics, Inc.
For more information, visit:
www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R.
Conafay, Principal, is a life-sciences government relations
firm based in Washington D.C. that
serves as Washington counsel and
coalition manager for AWG.
For more information, visit: www.conafaygroup.com
View original
content:http://www.prnewswire.com/news-releases/antimicrobials-working-group-highlights-member-company-participation-at-idweek-2019-300927885.html
SOURCE Antimicrobials Working Group (AWG)
